ONTX - Onconova Therapeutics (ONTX) - Clinical Trials Progressing As Expected As 1Q22 Reported

Onconova Reported 1Q22. Onconova reported a loss of $4.1 million or $(0.20) per share and gave updates to its clinical trial progress. The Phase 1 dose escalation trials for narazaciclib in solid organ tumors continue to treat patients. The trial in China continues to treat its fifth cohort, while the US trial continues to treat its fourth cohort. Rigosertib trials in non-small cell lung cancer and RDEB continue, with a new Phase 2 rigosertib trial in metastatic melanoma expected to begin during 2Q22.Narazacliclib Data To Be Presented At ASCO. An abstract on narazaciclib is scheduled for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3 to 7. We expect the data to include its action on CDK4, CDK6 and inhibition of targets in the pathways of cell proliferation, invasion, metastasis, and drug resistance. The studies will also show comparisons with the three approved CDK4/6 inhibitor drugs. Read More >>